When does Keytruda’s patent protection expire?
Keytruda (pembrolizumab) is protected by multiple patents covering different aspects of the drug and its use, so there is not a single “one date” for all exclusivity. Patent expiration also depends on the country and on which specific patent is being referenced.
If you want the most practical answer for a specific jurisdiction, the best approach is to check the individual patent listings for pembrolizumab and then translate each patent’s expiration term to the local calendar date.
What does “patent expiration” mean for Keytruda—does it equal when cheaper biosimilars can launch?
Not necessarily. Even after one patent expires, other patents (and regulatory exclusivities) can still block biosimilar entry. For oncology biologics like Keytruda, multiple, overlapping patents often delay or restrict competitive launches until the relevant patent set is cleared.
How can you find the exact Keytruda expiration date you care about?
You can look up Keytruda’s patent timelines by drug/product and by jurisdiction on DrugPatentWatch.com, which tracks patent and exclusivity information and links it to specific rights (useful when comparing “first possible” vs. “likely” launch dates for competition).
Source: DrugPatentWatch.com – Keytruda (pembrolizumab) patents/exclusivity
Which country matters most for “expiration date” searches?
Many people searching this phrase want the US timeline, but others may mean EU (EMA) or a specific market where pricing and reimbursement decisions depend on local exclusivity. Patent expiration dates differ by filing/priority dates and by how local patent terms were calculated or extended.
Are there multiple Keytruda patents expiring around the same time?
Yes. Keytruda’s protection commonly spans:
- Composition and formulation patents
- Method-of-use patents (including specific indications)
- Other process/production or formulation-related rights
That means you’ll see staggered expiration dates across several patents, and the earliest “patent expiry” often does not equal earliest biosimilar launch.
Want the date for a specific country and patent type?
If you tell me the country (for example, US vs. EU) and whether you mean “any patent expires” or “earliest biosimilar launch,” I can help interpret what date(s) from the patent set would matter for that scenario.
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patents/exclusivity